What is the recommended treatment for a confirmed Helicobacter pylori infection, including first‑line regimen, alternatives for penicillin allergy, and follow‑up testing?

Treatment of Confirmed Helicobacter pylori Infection

First-Line Regimen

Bismuth quadruple therapy for 14 days is the definitive first-line treatment for confirmed H. pylori infection, achieving 80–90% eradication rates even in regions with high clarithromycin and metronidazole resistance. 1

The regimen consists of:

• High-dose PPI twice daily (esomeprazole or rabeprazole 40 mg preferred, as they increase cure rates by 8–12% compared to standard PPIs) 1
• Bismuth subsalicylate 262 mg (two tablets) four times daily 1
• Metronidazole 500 mg three to four times daily 1
• Tetracycline 500 mg four times daily 1

Critical optimization factors:

• Take PPI 30 minutes before meals on an empty stomach, without concomitant antacids 1
• 14-day duration is mandatory—extending from 7 to 14 days improves eradication by approximately 5% 1, 2
• Never use pantoprazole due to markedly inferior acid-suppression potency 1

Why bismuth quadruple therapy is superior:

• No bacterial resistance to bismuth has been described 1
• Bismuth's synergistic effect overcomes metronidazole resistance in vitro 1
• Effective even against strains with dual clarithromycin-metronidazole resistance 1
• Uses antibiotics from the WHO "Access group" (tetracycline, metronidazole) rather than "Watch group" (clarithromycin, levofloxacin), making it preferable from an antimicrobial stewardship perspective 1

Alternative First-Line Option (When Bismuth Is Unavailable)

Concomitant non-bismuth quadruple therapy for 14 days may be used only in regions with documented clarithromycin resistance <15%: 1

• Esomeprazole or rabeprazole 40 mg twice daily 1
• Amoxicillin 1000 mg twice daily 1
• Clarithromycin 500 mg twice daily 1
• Metronidazole 500 mg twice daily 1

Do NOT use standard triple therapy (PPI + clarithromycin + amoxicillin) empirically—clarithromycin resistance now exceeds 15–20% in most of North America and Europe, reducing eradication rates to only 70% 1

---

Treatment for Penicillin Allergy

Bismuth quadruple therapy is the first-choice regimen for patients with penicillin allergy, as it contains tetracycline rather than amoxicillin. 1, 3

However, before accepting a penicillin allergy as definitive:

• Consider formal penicillin allergy testing after first-line failure, as most patients who report penicillin allergy do not have true anaphylaxis 3
• Delisting the allergy would enable amoxicillin-based regimens, which have rare resistance and significantly expand treatment options 3

If penicillin allergy is confirmed and bismuth quadruple therapy fails:

• Levofloxacin triple therapy (PPI 40 mg twice daily + metronidazole 500 mg twice daily + levofloxacin 500 mg once daily for 14 days) is the second-line option, only if the patient has no prior fluoroquinolone exposure 3

---

Second-Line Treatment After First-Line Failure

After clarithromycin-based triple therapy fails:

• Bismuth quadruple therapy for 14 days (if not previously used) 4, 1

After bismuth quadruple therapy fails:

• Levofloxacin triple therapy for 14 days (PPI twice daily + amoxicillin 1000 mg twice daily + levofloxacin 500 mg once daily), provided no prior fluoroquinolone exposure 4, 1
• Do NOT use levofloxacin if local resistance rates exceed 15% or if the patient has received any fluoroquinolone for any indication 4

Critical rule: Never repeat antibiotics that failed previously—especially clarithromycin and levofloxacin, where resistance develops rapidly after exposure and drops eradication rates from 90% to 20% 1

---

Third-Line and Rescue Therapies

After two failed eradication attempts with confirmed patient adherence, antibiotic susceptibility testing should guide further treatment whenever possible. 4, 1, 3, 2

Empiric third-line options when susceptibility testing is unavailable:

1. Rifabutin triple therapy for 14 days: 4, 1

   • Rifabutin 150 mg twice daily
   • Amoxicillin 1000 mg twice daily (or metronidazole 500 mg twice daily if penicillin-allergic)
   • High-dose PPI twice daily
   • Rifabutin resistance is rare, making this effective even after multiple failures 4

2. High-dose dual therapy for 14 days: 4, 1

   • Amoxicillin 2–3 grams daily divided into 3–4 doses
   • High-dose PPI (esomeprazole or rabeprazole 40 mg) twice daily
   • Reserved for patients who have exhausted other options 1

Only bismuth quadruple therapy (PBMT) is FDA-approved for refractory H. pylori infection. 4

---

Follow-Up Testing to Confirm Eradication

Test all patients for eradication success at least 4 weeks after therapy completion using urea breath test or validated monoclonal stool antigen test. 1, 3, 2

Critical testing requirements:

• Discontinue PPI at least 2 weeks (preferably 7–14 days) before testing to avoid false-negative results 1, 3
• Never use serology to confirm eradication—antibodies persist long after successful treatment 1, 3

Mandatory test-of-cure populations: 1

• Gastric ulcer (requires endoscopic surveillance to exclude malignancy)
• Complicated peptic ulcer disease
• Bleeding peptic ulcer
• Gastric MALT lymphoma

---

Common Pitfalls and How to Avoid Them

Pitfall 1: Using standard-dose PPI once daily

• This is a major cause of treatment failure 1
• Always prescribe high-dose PPI twice daily (esomeprazole or rabeprazole 40 mg preferred) 1

Pitfall 2: Shortening therapy to <14 days

• Reduces eradication success by approximately 5% 1, 2
• 14-day duration is mandatory for all regimens 1

Pitfall 3: Repeating the same failed regimen

• Guarantees failure and accelerates resistance 1
• Never reuse clarithromycin or levofloxacin if they were in a failed regimen 1

Pitfall 4: Ignoring patient factors that reduce success

• Smoking roughly doubles the odds of failure (OR 1.95)—advise cessation during therapy 4, 5
• Elevated BMI/obesity lowers gastric mucosal drug concentrations 4, 5
• Poor compliance is a leading cause of failure—provide clear written instructions and counsel on expected side effects (diarrhea occurs in 21–41% during the first week) 1, 5

Pitfall 5: Testing for cure too early or while on PPI

• Testing <4 weeks or while on PPI yields false-negative results 1, 3
• Wait at least 4 weeks after therapy and stop PPI at least 2 weeks before testing 1, 3

Pitfall 6: Using clarithromycin-based triple therapy empirically

• Clarithromycin resistance now exceeds 15–20% in most regions, making this regimen unacceptable without susceptibility testing 1, 2
• Bismuth quadruple therapy is superior and should be first-line 1